Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2021-11-10 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Code of Conduct under SEBI(PIT) Reg., 2015
Regulatory Filings Classification · 95% confidence The document is an intimation under SEBI (Prohibition of Insider Trading) Regulations, 2015, containing the company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). It details policies and procedures related to insider trading, disclosure of price sensitive information, and compliance with SEBI regulations. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or capital changes. It is a regulatory compliance document related to insider trading and disclosure practices. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-11-10 English
Updates
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on November 10, 2021, by Strides Pharma Science Limited. It includes approvals by the Board regarding continuation of an Independent Director, alteration of Articles of Association, and importantly, the reclassification of certain Promoters/Promoter Group shareholders to the 'Public' category. The document references compliance with SEBI Listing Regulations and includes extracts of minutes of the Board meeting approving these reclassifications. The content is focused on Board decisions and approvals rather than financial results or reports. There is no indication of financial statements, earnings data, or audit information. The document is not a proxy solicitation or voting results announcement but rather a formal disclosure of Board resolutions and management decisions. Therefore, the most appropriate classification is 'Board/Management Information' (MANG), as it announces changes and approvals made by the Board of Directors.
2021-11-10 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the approval by the Board of Directors for the reclassification of certain promoters/promoter group shareholders to the public category. It references Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes certified true copies of board meeting minutes approving the reclassification. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a board decision related to shareholding classification. It does not contain financial statements or detailed financial analysis. The content fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about shareholding reclassification and board resolutions, not a report or detailed financial disclosure.
2021-11-10 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is dated November 10, 2021, and is addressed to stock exchanges with scrip codes, indicating a formal corporate announcement. The subject line states 'Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2021.' The content includes detailed financial highlights for Q2FY22 and H1FY22, including revenues, EBITDA, PAT, EPS, and segment performance. There is commentary from the Managing Director & CEO on operational performance and outlook. The document also includes a press release and detailed investor communication on the company's quarterly and half-year financial results. The presence of unaudited financial results for a quarter and half year, along with detailed financial data and management commentary, aligns with an Interim / Quarterly Report. The document is comprehensive (15,000 characters), contains substantive financial data and analysis, and is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2022
2021-11-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification about an upcoming earnings call to discuss un-audited financial results for the quarter and half-year ended September 30, 2021. It includes details about the call timing, dial-in numbers, and mentions that the transcript will be posted later on the company's website. The document does not contain actual financial data or the transcript itself, but rather serves as an announcement for the earnings call event. Therefore, it is not an Earnings Release (ER) or Call Transcript (CT) but an announcement related to the earnings call. However, since it specifically announces the earnings call event, the best fitting category is Call Transcript (CT) as it is the closest category related to earnings call content announcements, even though the transcript is not included yet. Confidence is high due to clear mention of earnings call and related details.
2021-11-09 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short announcement addressed to stock exchanges regarding a scheduled Board Meeting to consider and approve unaudited financial results for a specific quarter and half year period. It references Regulation 29 of SEBI Listing Regulations, which pertains to disclosures about Board Meetings. The document does not contain any financial data or results itself, but merely informs about the upcoming meeting and trading window closure. The length is short (1236 characters), and it is clearly an announcement rather than a report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2021-11-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.